Short answer
Becton Dickinson (BDX) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $3.9B (down 25.1% year over year) with net income of −$310M.
Q1 2026 key financials · XBRL
- Revenue
- $3.9B
- −25.1% YoY · −24.8% QoQ
- Net income
- −$310M
- −200.6% YoY · −181.2% QoQ
- Operating margin
- 0.3%
- EPS (diluted)
- −$1.09
- −201.9% YoY · −181.3% QoQ
Source: XBRL data from the Becton Dickinson (BDX) Q1 2026 10-Q on SEC EDGAR. USD.
Becton Dickinson Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $4.714B, up 5.2% YoY from $4.480B, driven by volume/other 2.4% and foreign currency 2.6%
- Gross margin 45.7% vs 41.5% YoY, including 4.9% benefit from purchase-accounting and other specified items
- Best segment Interventional revenue $1.357B, up 7.3%; worst BioPharma Systems revenue $590M, up 2.5% but down 1.8% FX-neutral
- Operating cash flow $1.328B; cash and equivalents plus short-term investments $1.018B; $2.250B share repurchases
- Headwinds: tariffs expected to pressure fiscal 2026 operating expense; China VoBP and lower vaccine demand affecting results
Risk Factors
- No material changes to risk factors disclosed in BD’s 2025 Annual Report
- Financial risk: $2 billion accelerated share repurchase agreements executed in February 2026
- Capital-allocation risk: 9,319,664 initial ASR shares received, with final settlement due in fiscal Q3 2026
- Liquidity risk: $2 billion cash commitment under February 2026 ASR agreements
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Becton Dickinson quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.